(Q31936145)

5 July 2017

title

Telithromycin: a new ketolide antimicrobial for treatment of respiratory tract infections (English)

1 reference

5 July 2017

H M Yassin

1

1 reference

5 July 2017

L L Dever

series ordinal

2

1 reference

5 July 2017

language of work or name

English

0 references

publication date

1 February 2001

1 reference

Expert Opinion on Investigational Drugs

5 July 2017

published in

1 reference

5 July 2017

volume

10

1 reference

5 July 2017

issue

2

1 reference

5 July 2017

page(s)

353-367

1 reference

New research in macrolides and ketolides since 1997.

5 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.2.353

Inhibition of translation and 50S ribosomal subunit formation in Staphylococcus aureus cells by 11 different ketolide antibiotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.2.353

The in-vitro activity of HMR 3647, a new ketolide antimicrobial agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.2.353

In vitro activity of the novel ketolide HMR 3647 and comparative oral antibiotics against Canadian respiratory tract isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.2.353

In vitro activity of the new ketolide HMR 3004 compared to an azalide and macrolides against Streptococcus pneumoniae and Haemophilus influenzae.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.2.353

Comparative activities of telithromycin (HMR 3647), levofloxacin, and other antimicrobial agents against human mycoplasmas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.2.353

In vitro activities of the ketolides telithromycin (HMR 3647) and HMR 3004 compared to those of clarithromycin against slowly growing mycobacteria at pHs 6.8 and 7.4

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.2.353

In vitro activities of telithromycin (HMR 3647) against Rickettsia rickettsii, Rickettsia conorii, Rickettsia africae, Rickettsia typhi, Rickettsia prowazekii, Coxiella burnetii, Bartonella henselae, Bartonella quintana, Bartonella bacilliformis, an

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.2.353

In vitro development of resistance to telithromycin (HMR 3647), four macrolides, clindamycin, and pristinamycin in Streptococcus pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.2.353

Use of ketolides in combination with other drugs to treat experimental toxoplasmosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.2.353

A prediction rule to identify low-risk patients with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.2.353

Macrolide-ketolide inhibition of MLS-resistant ribosomes is improved by alternative drug interaction with domain II of 23S rRNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.2.353

10.1517/13543784.10.2.353

21 January 2018

Identifiers

DOI

1 reference

5 July 2017

1 reference